Table 1

Select efficacy results from HTX-011 phase III studies, EPOCH-1 (bunionectomy) and EPOCH-2 (herniorrhaphy)3–5

EPOCH-1EPOCH-2
Saline placebo
(n=100)
Bupivacaine HCl
50 mg
(n=155)
HTX-011
60 mg/1.8 mg
(n=157)
Saline placebo
(n=82)
Bupivacaine HCl
75 mg
(n=172)
HTX-011
300 mg/9 mg
(n=164)
Pain intensity
AUC0-24 of the NRS pain intensity scores
 Mean (SD)155.8 (48.49)131.4 (48.86)98.7 (59.55)143.8 (54.94)126.7 (52.68)97.7 (60.31)
 P value vs saline placebo0.0004<0.00010.0238<0.0001
 P value vs bupivacaine HCl<0.0001<0.0001
AUC24-72 of the NRS pain intensity scores
 Mean (SD)289.6 (115.64)262.1 (117.25)224.6 (131.28)207.1 (122.32)215.2 (111.97)171.7 (120.40)
 P value vs saline placebo0.0806<0.00010.60410.0264
 P value vs bupivacaine HCl0.00720.0007
Opioid use
Opioid consumption from 0 to 24 hours (MME)
 Mean (SD)14.1 (8.58)11.8 (9.39)7.4 (7.82)11.7 (10.82)7.3 (8.61)5.2 (7.86)
 Median (min, max)14.0 (0.0 to 45.0)10.0 (0.0 to 44.0)5.0 (0.0 to 29.0)9.8 (0.0 to 37.0)5.0 (0.0 to 37.0)0.0 (0.0 to 35.0)
 P value vs saline placebo<0.0001<0.0001
 P value vs bupivacaine HCl<0.00010.0073
Opioid consumption from 24 to 72 hours (MME)
 Mean (SD)15.9 (14.77)13.3 (14.56)11.4 (13.64)5.9 (9.30)7.2 (11.10)5.62 (11.09)
 Median (min, max)12.5 (0.0 to 60.0)8.0 (0.0 to 57.0)5.0 (0.0 to 54.0)0.0 (0.0 to 37.0)0.0 (0.0 to 69.0)0.0 (0.0 to 68.0)
 P value vs saline placebo0.00240.2532
 P value vs bupivacaine HCl0.15850.0161
Opioid-free
 % patients opioid-free through 72 hours2%11%29%22%40%51%
 P value vs saline placebo<0.0001<0.0001
 P value vs bupivacaine HCl0.00010.0486
  • AUC, area under the concentration time curve; MME, morphine milligram equivalents; NRS, numeric rating scale.